Brenda Moore, DO
Family Medicine · Gallup, NMNPI 1275824120
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,669 and has fallen 96.2% since, to $64 in 2023. Among family medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$475
- GSK$443
- AstraZeneca$376
- Novo Nordisk$372
- Amgen$308
- Lilly USA, LLC$290
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 29 | $475 |
| GSK | 22 | $443 |
| AstraZeneca | 24 | $376 |
| Novo Nordisk | 24 | $372 |
| Amgen | 21 | $308 |
| Lilly USA, LLC | 23 | $290 |
| Merck | 20 | $272 |
| Teva Pharmaceuticals USA, Inc. | 11 | $240 |
| Boehringer Ingelheim | 11 | $201 |
| AbbVie(2 entities) | 10 | $172 |
| Eisai Inc. | 10 | $144 |
| Pfizer | 10 | $143 |
| Jazz Pharmaceuticals Inc. | 7 | $121 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $98 |
| Biohaven Pharmaceuticals, Inc. | 6 | $96 |
| Amarin Pharma, Inc. | 5 | $92 |
| Kowa Pharmaceuticals America, Inc. | 7 | $91 |
| Clarus Therapeutics Inc. | 8 | $89 |
| Arbor Pharmaceuticals, Inc. | 5 | $61 |
| Abbott | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Novartis | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 2 | $28 |
| GRT US Holding, Inc. | 1 | $27 |
| Circassia Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$4,512 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $48,875 |
| EliquisApixaban | 29 | $17,549 |
| OzempicSemaglutide | 13 | $13,563 |
| XareltoRivaroxaban | 18 | $9,994 |
| MyrbetriqMirabegron | 16 | $7,598 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,338 |
| Novolog FlexpenInsulin Aspart | 16 | $2,011 |
| SynthroidLevothyroxine Sodium | 76 | $1,829 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,527 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $1,063 |
| Losartan Potassium | 80 | $435 |
| Gabapentin | 55 | $322 |
| Hydroxyzine Hcl | 16 | $287 |
| Diclofenac Sodium | 54 | $256 |
| Atorvastatin Calcium | 80 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $201 | $48,87578 claims |
| PfizerEliquis | $143 | $17,54929 claims |
| Novo NordiskOzempic | $372 | $13,56313 claims |
| Astellas Pharma US IncMyrbetriq | $475 | $7,59816 claims |
| AbbVieSynthroid | $172 | $1,82976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Gallup
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
- Wendy JohnsonSanta Fe$37K
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Sergio HuertaLas Cruces$11K
- Timothy GrenemyerAlbuquerque$10K
- Cheri BlackstenAlbuquerque$9K
- Brenda CuellarLas Cruces$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.